Pre-release: this release has not been published. Identifiers are permanent; descriptions may still change.
21 U.S.C. 356c Discontinuance or interruption in the production of life-saving drugs
21 U.S.C. 356c Discontinuance or interruption in the production of life-saving drugs, “Discontinuance or interruption in the production of life-saving drugs”, is a U.S. Code section of Part A—Drugs and Devices; in force.
https://ontology.bommaritollc.com/id/01a0f06c-cceb-7622-a6eb-e8aae47a19b5
Elsewhere
Facts
| adms:identifier | |
| eli:cites | |
| prov:wasDerivedFrom | |
| schema:isPartOf | |
| schema:legislationIdentifier | 21 U.S.C. 356c |
| schema:legislationJurisdiction | |
| schema:legislationLegalForce | |
| schema:legislationType | |
| schema:name | Discontinuance or interruption in the production of life-saving drugsen |
| schema:url | |
| skos:prefLabel | 21 U.S.C. 356c Discontinuance or interruption in the production of life-saving drugsen |
Related
Cited by (6)eli:cites
- 21 CFR 314.81 Other postmarketing reports.
- 21 CFR 600.82 Notification of a permanent discontinuance or an interruption in manufacturing.
- 21 U.S.C. 356c-1 Annual reporting on drug shortages
- 21 U.S.C. 356d Coordination; task force and strategic plan
- 21 U.S.C. 356e Drug shortage list
- 21 U.S.C. 374 Inspection
Amended by (4)eli:amends
Rules made under it (3)eli:based_on
- 21 CFR Part 230—Certification and postmarketing reporting for designated medical gases (Eff. 12-18-25)
- 21 CFR Part 314—Applications for FDA approval to market a new drug
- 21 CFR Part 600—Biological products: general